UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 136

Sortiert nach

Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991–2001

JNCI : Journal of the National Cancer Institute, 2002-12, Vol.94 (24), p.1883-1888

2002

Volltextzugriff (PDF)

Novel Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Tumor Vaccine for Pancreatic Cancer: A Phase I Trial of Safety and Immune Activation

Journal of clinical oncology, 2001-01, Vol.19 (1), p.145-156

2001

Volltextzugriff (PDF)

Chemotherapy for Human Immunodeficiency Virus–Associated Non-Hodgkin’s Lymphoma in Combination With Highly Active Antiretroviral Therapy

Journal of clinical oncology, 2001-04, Vol.19 (8), p.2171-2178

2001

Volltextzugriff (PDF)

Clinical potential of matrix metalloprotease inhibitors in cancer therapy

Drugs (New York, N.Y.), 2000-05, Vol.59 (5), p.1043-1055

2000

Volltextzugriff (PDF)

Busulfan disposition : the role of therapeutic monitoring in bone marrow transplantation induction regimens

Seminars in oncology, 1993-08, Vol.20 (4), p.18-25

GROCHOW, L. B

1993

Volltextzugriff (PDF)

A Phase I Clinical and Pharmacological Evaluation of Sodium Phenylbutyrate on an 120-h Infusion Schedule

Clinical cancer research, 2001-10, Vol.7 (10), p.3047-3055

2001

Volltextzugriff (PDF)

Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes

Annals of surgery, 1997-09, Vol.226 (3), p.248-260

1997

Volltextzugriff (PDF)

Phase I and pharmacologic study of topotecan in patients with impaired renal function

Journal of clinical oncology, 1996-12, Vol.14 (12), p.3062-3073

1996

Volltextzugriff (PDF)

Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence

Journal of clinical oncology, 1996-12, Vol.14 (12), p.3074-3084

1996

Volltextzugriff (PDF)

A Prospective Pharmacologic Evaluation of Age-Related Toxicity of Adjuvant Chemotherapy in Women with Breast Cancer

Cancer investigation, 2000, Vol.18 (6), p.521-529

2000

Volltextzugriff (PDF)

Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase

Journal of clinical oncology, 1996-12, Vol.14 (12), p.3085-3096

1996

Volltextzugriff (PDF)

Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience

Annals of surgery, 1997-05, Vol.225 (5), p.621-636

1997

Volltextzugriff (PDF)

Toxicity, Efficacy, and Pharmacology of Suramin in Adults With Recurrent High-Grade Gliomas

Journal of clinical oncology, 2001-07, Vol.19 (13), p.3260-3266

2001

Volltextzugriff (PDF)

Cytotoxic Effects of Topotecan Combined With Various Anticancer Agents in Human Cancer Cell Lines

JNCI : Journal of the National Cancer Institute, 1996-06, Vol.88 (11), p.734-741

1996

Volltextzugriff (PDF)

Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels

International journal of radiation oncology, biology, physics, 1999-07, Vol.44 (5), p.1039-1046

1999

Volltextzugriff (PDF)

Population Pharmacokinetic Model for Topotecan Derived From Phase I Clinical Trials

Journal of clinical oncology, 2000-06, Vol.18 (12), p.2459-2467

2000

Volltextzugriff (PDF)

Pharmacology of Cancer Chemotherapy in the Older Person

Clinics in geriatric medicine, 1997-02, Vol.13 (1), p.169-183

1997

Volltextzugriff (PDF)

Phase I and Pharmacologic Study of Oral Fluorouracil on a Chronic Daily Schedule in Combination With the Dihydropyrimidine Dehydrogenase Inactivator Eniluracil

Journal of clinical oncology, 2000-02, Vol.18 (4), p.915-926

2000

Volltextzugriff (PDF)

Impact of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia

Clinical cancer research, 2001-08, Vol.7 (8), p.2330-2339

2001

Volltextzugriff (PDF)

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

Journal of clinical oncology, 1992-04, Vol.10 (4), p.647-656

1992

Volltextzugriff (PDF)

Sequences of taxol and cisplatin: a phase I and pharmacologic study

Journal of clinical oncology, 1991-09, Vol.9 (9), p.1692-1703

1991

Volltextzugriff (PDF)

Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864); a new camptothecin analogue

Cancer research (Chicago, Ill.), 1992-04, Vol.52 (8), p.2268-2278

1992

Volltextzugriff (PDF)

Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks

Cancer research (Chicago, Ill.), 1994-01, Vol.54 (2), p.427-436

1994

Volltextzugriff (PDF)

Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2001-10, Vol.48 (4), p.269-274

2001

Volltextzugriff (PDF)

Phase I and Pharmacologic Studies of Topotecan in Patients With Impaired Hepatic Function

JNCI : Journal of the National Cancer Institute, 1996-06, Vol.88 (12), p.817-824

1996

Volltextzugriff (PDF)

1 – 25 von 136

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(127)
Mit Volltextzugriff
(120)

Publikationsform

Artikel
(133)
Tagungsberichte
(3)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(103)
Science & Technology
(95)
Life Sciences & Biomedicine
(92)
Biological And Medical Sciences
(85)
Medical Sciences
(83)
Pharmacology. Drug Treatments
(71)
Female
(70)
Middle Aged
(66)
Adult
(65)
Male
(64)
Oncology
(64)
Antineoplastic Agents
(62)
Aged
(56)
Chemotherapy
(53)
Dose-Response Relationship, Drug
(31)
Neoplasms - Drug Therapy
(29)
Drug Administration Schedule
(24)
Antineoplastic Agents - Adverse Effects
(22)
Antineoplastic Agents - Therapeutic Use
(21)
Infusions, Intravenous
(20)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991–2001

Novel Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Tumor Vaccine for Pancreatic Cancer: A Phase I Trial of Safety and Immune Activation

Chemotherapy for Human Immunodeficiency Virus–Associated Non-Hodgkin’s Lymphoma in Combination With Highly Active Antiretroviral Therapy

Clinical potential of matrix metalloprotease inhibitors in cancer therapy

Busulfan disposition : the role of therapeutic monitoring in bone marrow transplantation induction regimens

A Phase I Clinical and Pharmacological Evaluation of Sodium Phenylbutyrate on an 120-h Infusion Schedule

Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes

Phase I and pharmacologic study of topotecan in patients with impaired renal function

Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence

A Prospective Pharmacologic Evaluation of Age-Related Toxicity of Adjuvant Chemotherapy in Women with Breast Cancer

Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase

Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience

Toxicity, Efficacy, and Pharmacology of Suramin in Adults With Recurrent High-Grade Gliomas

Cytotoxic Effects of Topotecan Combined With Various Anticancer Agents in Human Cancer Cell Lines

Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels

Population Pharmacokinetic Model for Topotecan Derived From Phase I Clinical Trials

Pharmacology of Cancer Chemotherapy in the Older Person

Phase I and Pharmacologic Study of Oral Fluorouracil on a Chronic Daily Schedule in Combination With the Dihydropyrimidine Dehydrogenase Inactivator Eniluracil

Impact of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

Sequences of taxol and cisplatin: a phase I and pharmacologic study

Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864); a new camptothecin analogue

Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks

Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors

Phase I and Pharmacologic Studies of Topotecan in Patients With Impaired Hepatic Function

Suchergebnisse filtern